GlassScriptPhysician profile
Robert Jerome Fleming
NPI 1477214864
$728.09
in general payments reported to CMS, 2019-2025
21 companies · $532 in 2025
The $532 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $196 · 2025: $532.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $728.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $728.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $103.17 | 2024-2025 | Wegovy, Ozempic |
| Abbvie INC. | $77.67 | 2025 | |
| Lilly USA, LLC | $76.32 | 2024-2025 | Zepbound, Mounjaro, Jardiance |
| Xeris Pharmaceuticals, INC. | $63.20 | 2025 | Gvoke Hypopen |
| Pfizer INC. | $46.99 | 2024-2025 | |
| Amgen INC. | $36.85 | 2024-2025 | Otezla, Repatha, Repatha |
| Boston Scientific Corporation | $34.26 | 2025 | Intracept |
| Dexcom, INC. | $32.88 | 2025 | Dexcom G6 Transmitter |
| Medtronic, INC. | $32.35 | 2025 | Minimed 780g |
| Exact Sciences Corporation | $30.01 | 2025 | Cologuard Collection Kit |
| Beta Bionics, INC. | $24.09 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Averitas Pharma INC. | $20.11 | 2024 | Qutenza |
| Glaxosmithkline, LLC. | $18.32 | 2025 | Shingrix, Arexvy |
| Valinor Pharma, LLC | $18.31 | 2025 | Movantik |
| E.R. Squibb & Sons, L.L.C. | $17.67 | 2025 | Eliquis |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $17.41 | 2024 | Dyanavel Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $17.04 | 2025 | Caplyta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.02 | 2025 | Xifaxan |
| Novartis Pharmaceuticals Corporation | $15.48 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.04 | 2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $14.90 | 2025 | Airsupra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Fleming listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.